Results 161 to 170 of about 96,147 (311)

Machine Learning Approach Enables Highly Accurate Identification of At‐Risk Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
ABSTRACT Aim At‐risk metabolic dysfunction‐associated steatohepatitis (MASH), characterized by significant activity and fibrosis, increases the risk of liver complications. Liver stiffness measurement (LSM), commonly used to detect significant fibrosis, has limitations in terms of accessibility and performance in certain populations.
Masaya Sato, Takuma Nakatsuka, Tatsuya Minami, Yotaro Kudo, Rie Irie, Hanako Tsujikawa, Takumi Kawaguchi, Hirokazu Takahashi, Yuichiro Eguchi, Eisuke Murakami, Kazuaki Chayama, Takeshi Okanoue, Michiie Sakamoto, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +15 more
wiley   +1 more source

Splenic Artery Aneurysm With Arterioportal Fistula: An Unusual Cause of Portal Hypertension. [PDF]

Cureus
Dubhashi R, Kumar S, Subramaniam S.
europepmc   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Simvastatin combined with antiviral therapy for hepatitis B cirrhosis with portal hypertension: A case report. [PDF]

Medicine (Baltimore)
Zhang H, Li J, Zhou Y, Li X, Wang H, Gou W, Liu Z, Qi X.   +7 more
europepmc   +1 more source

Clinical evaluation of porto-systemic collaterals in patients with portal hypertension.

, 1986
Shuichi Ishiyama, Nobuo SEO, Akira Fuse, Shigeru Katagiri, Hajime IIZAWA, Hiroshi Kawamura, J Kameyama, Masaru Tsukamoto   +7 more
openalex   +2 more sources

Diagnosing Systemic Mastocytosis: State of the Art

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley   +1 more source

The pathophysiological role of portal hypertension in metabolic dysfunction-associated steatotic liver disease. [PDF]

Hepatol Commun
Møller S, Sjöstedt SMS, Hobolth L, Mortensen C, Mortensen C, Kimer N.   +5 more
europepmc   +1 more source

Periodontitis and Periodontal Conditions in Systemically Healthy Children and Adolescents

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Objective To answer the PICoS question ‘in systemically healthy children and adolescents (Population), what are the main features of periodontitis, necrotising periodontal diseases (NPD) and other periodontal conditions (periodontal abscesses, endo‐periodontal lesions, traumatic occlusal forces, prosthesis‐ and tooth‐related factors ...
Inbar Eshkol‐Yogev, Nagore Ambrosio, Cheryl Somani, Elena Figuero, Lior Shapira, Janet Davies   +5 more
wiley   +1 more source

Functional Shunt with Small-for-Size Graft in Auxiliary Liver Transplantation for Portal Hypertension. [PDF]

Ann Transplant
Qu W, Liu Y, Cai RZ, Zhu ZJ, Sun LY, Wei L, Zeng ZG.   +6 more
europepmc   +1 more source

Noncirrhotic Portal Hypertension – A Case Report on a Sequela of Portal Vein Cavernoma

ISAAC MAWUNYEGA KWAKU AHORKLO, WILLIAM ERZUAH ARTHUR, DELA WORDI   +2 more
openalex   +2 more sources